Expression of different RASSF1 transcripts and its clinical significance in lung carcinoma.
- Author:
Kang SHAO
1
;
Jie HE
;
Bang-chang CHENG
;
Zhi-xiong XIAO
;
De-chao ZHANG
;
Wei HUANG
;
Cui-yan ZHANG
;
Fang ZHOU
;
Mei-hua XIONG
;
Huai-jing TANG
;
Su-sheng SHI
;
Ba-dong MU
Author Information
- Publication Type:Journal Article
- MeSH: Chromosome Deletion; Chromosomes, Human, Pair 3; Genes, Tumor Suppressor; Humans; Lung Neoplasms; genetics; pathology; Lymphatic Metastasis; Neoplasm Staging; RNA, Messenger; analysis; Tumor Suppressor Proteins; genetics
- From: Chinese Journal of Oncology 2003;25(2):149-152
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the expression of three different RASSF1 transcripts and its clinical significance in lung carcinomas.
METHODSThe mRNA expression of RASSF1A, RASSF1B and RASSF1C was detected by RT-PCR in 51 human lung cancer tissues and 51 matched normal tissues.
RESULTS1. The mRNA expression of three RASSF1 transcripts was detectable in all non-cancer tissues. However, high rate of expression loss of RASSF1A and RASSF1B existed in lung cancer tissues, which was 53.2% (2851) and 37.3% (19/51), respectively. RASSF1C was expressed in all of the tumor tissues. 2. Loss or abnormal down-regulation of RASSF1A was positively related with lymph node metastasis and TNM stage (P < 0.05) and 3. RASSF1B and RASSF1C mRNA expression was not correlated with TNM stage, histological type, differentiation grade or smoking index.
CONCLUSIONThere is a significant expression difference among the three RASSF1 transcripts in lung carcinoma. RASSF1A, closely associated with lymph metastasis and TNM stage of lung carcinoma, should be a new tumor suppressor gene.
